The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1
Open accessAbstract
Background: Organic anion transporting polypeptide (OATP) 1B1, OATP1B3, and OATP2B1 (encoded by SLCO1B1, SLCO1B3, SLCO2B1) mediate the hepatic uptake of endogenous compounds like bile acids and of drugs, for example, the lipid-lowering atorvastatin, thereby influencing hepatobiliary elimination. Here we systematically elucidated the contribution of SLCO variants on expression of the three hepatic OATPs under consideration of additional important covariates. Methods: Expression was quantified by RT-PCR and immunoblotting in 143 Caucasian liver samples. A total of 109 rare and common variants in the SLCO1B3-SLCO1B1 genomic region and the SLCO2B1 gene were genotyped by MALDI-TOF mass spectrometry and genome-wide SNP microarray technology. SLCO1B1 haplotypes affecting hepatic OATP1B1 expression were associated with pharmacokinetic data of the OATP1B1 substrate atorvastatin (n = 82). Results: Expression of OATP1B1, OATP1B3, and OATP2B1 at the mRNA and protein levels showed marked interindividual variability. All three OATPs were expressed in a coordinated fashion. By a multivariate regression analysis adjusted for non-genetic and transcription covariates, increased OATP1B1 expression was associated with the coding SLCO1B1 variant c.388A > G (rs2306283) even after correction for multiple testing (P = 0.00034). This held true for haplotypes harboring c.388A > G but not the functional variant c.521T > C (rs4149056) associated with statin-related myopathy. c.388A > G also significantly affected atorvastatin pharmacokinetics. SLCO variants and non-genetic and regulatory covariates together accounted for 59% of variability of OATP1B1 expression. Conclusions: Our results show that expression of OATP1B1, but not of OATP1B3 and OATP2B1, is significantly affected by genetic variants. The SLCO1B1 variant c.388A > G is the major determinant with additional consequences on atorvastatin plasma levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Simple Sequentially Rejective Multiple Test Procedure
(1979) · Scandinavian Journal of Statistics · doi:10.2307/4615733 · Cited by 21,526
Haploview: analysis and visualization of LD and haplotype maps
Barrett, J. C., Fry, B., Maller, J., & Daly, M. J. (2005) · Bioinformatics · doi:10.1093/bioinformatics/bth457 · Cited by 14,525
Mfold web server for nucleic acid folding and hybridization prediction
Zuker, M. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg595 · Cited by 13,404
A method and server for predicting damaging missense mutations.
Adzhubei, I. A., Schmidt, S., Peshkin, L., Ramensky, V. E., Gerasimova, A., Bork, P., Kondrashov, A. S., & Sunyaev, S. R. (2010) · Nature Methods · doi:10.1038/nmeth0410-248 · Cited by 13,194
Kumar, P., Henikoff, S., & Ng, P. C. (2009) · Nature Protocols · doi:10.1038/nprot.2009.86 · Cited by 6,521
Mathews, D. H., Sabina, J., Zuker, M., & Turner, D. H. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.2700 · Cited by 3,795
Membrane transporters in drug development
The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3028 · Cited by 3,340
Self-citationThe R Project in Statistical Computing
Ripley, B. D. (2001) · MSOR Connections · doi:10.11120/msor.2001.01010023 · Cited by 2,529
Clinical Guide to Laboratory Tests.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-821-7 · Cited by 2,139
SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043
A Note on Exact Tests of Hardy-Weinberg Equilibrium
Wigginton, J. E., Cutler, D. J., & Abecasis, G. R. (2005) · The American Journal of Human Genetics · doi:10.1086/429864 · Cited by 1,446
Criteria of drug-induced liver disorders
(1990) · Journal of Hepatology · doi:10.1016/0168-8278(90)90124-a · Cited by 1,106
Hagenbuch, B., & Meier, P. J. (2004) · Pfl�gers Archiv European Journal of Physiology · doi:10.1007/s00424-003-1168-y · Cited by 1,019
Nuclear Receptor Response Elements Mediate Induction of Intestinal MDR1 by Rifampin
Geick, A., Eichelbaum, M., & Burk, O. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010173200 · Cited by 848
Self-citationKullak-Ublick, G. A., Ismair, M. G., Stieger, B., Landmann, L., Huber, R., Pizzagalli, F., Fattinger, K., Meier, P. J., & Hagenbuch, B. (2001) · Gastroenterology · doi:10.1053/gast.2001.21176 · Cited by 723
Self-citationNiemi, M., Pasanen, M. K., & Neuvonen, P. J. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.002857 · Cited by 633
Self-citationTirona, R. G., Leake, B. F., Merino, G., & Kim, R. B. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103792200 · Cited by 626
König, J., Cui, Y., Nies, A. T., & Keppler, D. (2000) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.2000.278.1.g156 · Cited by 620
Self-citationHo, R. H., Tirona, R. G., Leake, B. F., Glaeser, H., Lee, W., Lemke, C. J., Wang, Y., & Kim, R. B. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.02.034 · Cited by 611
Lang, T., Klein, K., Fischer, J., Nussler, A. K., Neuhaus, P., Hofmann, U., Eichelbaum, M., Schwab, M. G., & Zanger, U. M. (2001) · Pharmacogenetics · doi:10.1097/00008571-200107000-00004 · Cited by 574
Self-citationSex Is A Major Determinant of Cyp3a4 Expression in Human Liver
Wolbold, R., Klein, K., Burk, O., Nüssler, A. K., Neuhaus, P., Eichelbaum, M., Schwab, M., & Zanger, U. M. (2003) · Hepatology · doi:10.1002/hep.1840380424 · Cited by 529
Self-citationTransporters and drug therapy: Implications for drug disposition and disease
HO, R., & KIM, R. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.05.011 · Cited by 502
The SLCO1B1*5Genetic Variant Is Associated With Statin-Induced Side Effects
Voora, D., Shah, S. H., Spasojevic, I., Ali, S., Reed, C. R., Salisbury, B. A., & Ginsburg, G. S. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.053 · Cited by 502
LEE, E., RYAN, S., BIRMINGHAM, B., ZALIKOWSKI, J., MARCH, R., AMBROSE, H., MOORE, R., LEE, C., CHEN, Y., & SCHNECK, D. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.013 · Cited by 480
SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid
Pasanen, M. K., Neuvonen, M., Neuvonen, P. J., & Niemi, M. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000230416.82349.90 · Cited by 470
Self-citationSNPs3D: Candidate gene and SNP selection for association studies
Yue, P., Melamud, E., & Moult, J. (2006) · BMC Bioinformatics · doi:10.1186/1471-2105-7-166 · Cited by 464
Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin
Pasanen, M. K., Fredrikson, H., Neuvonen, P. J., & Niemi, M. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100220 · Cited by 432
Self-citationABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin
Keskitalo, J. E., Zolk, O., Fromm, M. F., Kurkinen, K. J., Neuvonen, P. J., & Niemi, M. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.79 · Cited by 416
Self-citationSLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid
Tornio, A., Vakkilainen, J., Neuvonen, M., Backman, J. T., Neuvonen, P. J., & Niemi, M. (2015) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000148 · Cited by 409
Self-citationNies, A. T., Koepsell, H., Winter, S., Burk, O., Klein, K., Kerb, R., Zanger, U. M., Keppler, D., Schwab, M., & Schaeffeler, E. (2009) · Hepatology · doi:10.1002/hep.23103 · Cited by 387
Self-citationvan de Steeg, E., Stránecký, V., Hartmannová, H., Nosková, L., Hřebíček, M., Wagenaar, E., van Esch, A., de Waart, D. R., Oude Elferink, R. P. J., Kenworthy, K. E., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59526 · Cited by 384
Kameyama, Y., Yamashita, K., Kobayashi, K., Hosokawa, M., & Chiba, K. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000170913.73780.5f · Cited by 379
Clinical Guide to Laboratory Tests.
(1984) · Annals of Internal Medicine · doi:10.7326/0003-4819-100-5-774_3 · Cited by 373
Nozawa, T., Nakajima, M., Tamai, I., Noda, K., Nezu, J.-I., Sai, Y., Tsuji, A., & Yokoi, T. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.302.2.804 · Cited by 318
Jigorel, E., Le Vee, M., Boursier-Neyret, C., Parmentier, Y., & Fardel, O. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.010033 · Cited by 315
Evidence for inverse effects of OATP-C (SLC21A6) *5 and *1b haplotypes on pravastatin kinetics
Mwinyi, J. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.12.016 · Cited by 293
Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition
Ramsey, L. B., Bruun, G. H., Yang, W., Treviño, L. R., Vattathil, S., Scheet, P., Cheng, C., Rosner, G. L., Giacomini, K. M., Fan, Y., et al. (2012) · Genome Research · doi:10.1101/gr.129668.111 · Cited by 261
New molecular insights into the mechanisms of cholestasis
Wagner, M., Zollner, G., & Trauner, M. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.05.012 · Cited by 260
Meier, Y., Pauli-Magnus, C., Zanger, U. M., Klein, K., Schaeffeler, E., Nussler, A. K., Nussler, N., Eichelbaum, M., Meier, P. J., & Stieger, B. (2006) · Hepatology · doi:10.1002/hep.21214 · Cited by 219
Self-citationDonnelly, L. A., Doney, A. S. F., Tavendale, R., Lang, C. C., Pearson, E. R., Colhoun, H. M., McCarthy, M. I., Hattersley, A. T., Morris, A. D., & Palmer, C. N. A. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.255 · Cited by 203
Bartoszewski, R. A., Jablonsky, M., Bartoszewska, S., Stevenson, L., Dai, Q., Kappes, J., Collawn, J. F., & Bebok, Z. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.154575 · Cited by 202
MAEDA, K., IEIRI, I., YASUDA, K., FUJINO, A., FUJIWARA, H., OTSUBO, K., HIRANO, M., WATANABE, T., KITAMURA, Y., & KUSUHARA, H. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.01.011 · Cited by 200
Brunham, L. R., Lansberg, P. J., Zhang, L., Miao, F., Carter, C., Hovingh, G. K., Visscher, H., Jukema, J. W., Stalenhoef, A. F., Ross, C. J. D., et al. (2012) · The Pharmacogenomics Journal · doi:10.1038/tpj.2010.92 · Cited by 199
Human Hepatobiliary Transport of Organic Anions Analyzed by Quadruple-Transfected Cells
Kopplow, K., Letschert, K., König, J., Walter, B., & Keppler, D. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.014605 · Cited by 197
Proton Pump Inhibitors Inhibit Metformin Uptake by Organic Cation Transporters (OCTs)
Nies, A. T., Hofmann, U., Resch, C., Schaeffeler, E., Rius, M., & Schwab, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022163 · Cited by 184
Self-citationEffect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3
Gui, C., Miao, Y., Thompson, L., Wahlgren, B., Mock, M., Stieger, B., & Hagenbuch, B. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.01.042 · Cited by 174
Self-citationJung, D., Podvinec, M., Meyer, U. A., Mangelsdorf, D. J., Fried, M., Meier, P. J., & Kullak–Ublick, G. A. (2002) · Gastroenterology · doi:10.1053/gast.2002.33583 · Cited by 170
Jung, D., Hagenbuch, B., Gresh, L., Pontoglio, M., Meier, P. J., & Kullak-Ublick, G. A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103988200 · Cited by 170
Sequence‐based prediction of pathological mutations
Ferrer‐Costa, C., Orozco, M., & de la Cruz, X. (2004) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.20252 · Cited by 163
Borel, F., Han, R., Visser, A., Petry, H., van Deventer, S. J. H., Jansen, P. L. M., & Konstantinova, P. S. (2011) · Hepatology · doi:10.1002/hep.24682 · Cited by 157
Keskitalo, J. E., Kurkinen, K. J., Neuvonen, P. J., & Niemi, M. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.25 · Cited by 149
Self-citationSchaeffeler, E., Hellerbrand, C., Nies, A. T., Winter, S., Kruck, S., Hofmann, U., van der Kuip, H., Zanger, U. M., Koepsell, H., & Schwab, M. G. (2011) · Genome Medicine · doi:10.1186/gm298 · Cited by 149
Self-citationIwai, M., Suzuki, H., Ieiri, I., Otsubo, K., & Sugiyama, Y. (2004) · Pharmacogenetics · doi:10.1097/00008571-200411000-00006 · Cited by 147
Nies, A. T., Herrmann, E., Brom, M., & KEPPLER, D. O. R. (2007) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-007-0219-x · Cited by 124
Self-citationNies, A. T., Schwab, M. G., & KEPPLER, D. O. R. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.5.545 · Cited by 122
Self-citationRaymond, É., Boige, V., Faivre, S. J., Sanderink, G., Rixe, O., Vernillet, L., Jacques, C. J., Gatineau, M., Ducreux, M. P., & Armand, J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.03.123 · Cited by 119
Cui, Y., König, J., Nies, A. T., Pfannschmidt, M., Hergt, M., Franke, W. W., Alt, W., Moll, R., & KEPPLER, D. O. R. (2003) · Laboratory Investigation · doi:10.1097/01.lab.0000065015.02412.48 · Cited by 116
Self-citationVavricka, S. R., Jung, D., Fried, M., Grützner, U., Meier, P. J., & Kullak-Ublick, G. A. (2003) · Journal of Hepatology · doi:10.1016/j.jhep.2003.10.008 · Cited by 112
Schröder, A., Klein, K., Winter, S., Schwab, M. G., Bonin, M., Zell, A., & Zanger, U. M. (2011) · The Pharmacogenomics Journal · doi:10.1038/tpj.2011.44 · Cited by 106
Self-citationZukunft, J., Lang, T., Richter, T., Hirsch‐Ernst, K. I., Nussler, A. K., Klein, K., Schwab, M. G., Eichelbaum, M. F., & Zanger, U. M. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.008086 · Cited by 105
Self-citationPathway-Targeted Pharmacogenomics of CYP1A2 in Human Liver
Klein, K., Winter, S., Turpeinen, M., Schwab, M. G., & Zanger, U. M. (2010) · Frontiers in Pharmacology · doi:10.3389/fphar.2010.00129 · Cited by 99
Self-citationLiver X Receptor α and Farnesoid X Receptor Are Major Transcriptional Regulators of OATP1B1
zu Schwabedissen, H. E. M., Böttcher, K., Chaudhry, A. S., Kroemer, H. K., Schuetz, E. G., & Kim, R. B. (2010) · Hepatology · doi:10.1002/hep.23876 · Cited by 84
Choi, M., Shin, H. J., Choi, Y. L., Deng, J., Shin, J., & Song, I. (2010) · Xenobiotica · doi:10.3109/00498254.2010.523736 · Cited by 77
Kusuhara, H., & Sugiyama, Y. (2010) · Drug Metabolism Reviews · doi:10.3109/03602530903491824 · Cited by 73
Kalliokoski, A., Backman, J. T., Neuvonen, P. J., & Niemi, M. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32830d733e · Cited by 68
Self-citationRodrigues, A. C., Perin, P. M., Purim, S. G., Silbiger, V. N., Genvigir, F. D. V., Willrich, M. A. V., Arazi, S. S., Luchessi, A. D., Hirata, M. H., Bernik, M. M. S., et al. (2011) · International Journal of Molecular Sciences · doi:10.3390/ijms12095815 · Cited by 60
Tegude, H., Schnabel, A., Zanger, U. M., Klein, K., Eichelbaum, M. F., & Burk, O. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.013565 · Cited by 47
Self-citationRegulation of drug transporter expression by oncostatin M in human hepatocytes
Vée, M. L., Jouan, E., Stieger, B., Lecureur, V., & Fardel, O. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.04.017 · Cited by 39
Self-citationOhtsuka, H., Abe, T., Onogawa, T., Kondo, N., Sato, T., Oshio, H., Mizutamari, H., Mikkaichi, T., Oikawa, M., Rikiyama, T., et al. (2006) · Journal of Gastroenterology · doi:10.1007/s00535-006-1784-3 · Cited by 39
Clarke, J., & Cherrington, N. J. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.656087 · Cited by 33
Furihata, T., Satoh, T., Yamamoto, N., et al. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9458-2 · Cited by 26
Locker, J. D. (2002) · Nucleic Acids Research · doi:10.1093/nar/gkf484 · Cited by 26
Transcriptional control of human organic anion transporting polypeptide 2B1 gene
Pomari, E., Nardi, A., Fiore, C., Celeghin, A., Colombo, L., & Valle, L. D. (2009) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2009.04.003 · Cited by 18
Seminari, E. M., Gentilini, G., Galli, L., Hasson, H., Danise, A., Carini, E., Dorigatti, F., Soldarini, A., Lazzarin, A., & Castagna, A. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki314 · Cited by 16
Cited by
Transporters and Drug-Drug Interactions: Important Determinants of Drug Disposition and Effects
König, J., Müller, F., & Fromm, M. F. (2013) · Pharmacological Reviews · doi:10.1124/pr.113.007518 · Cited by 575
SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid
Tornio, A., Vakkilainen, J., Neuvonen, M., Backman, J. T., Neuvonen, P. J., & Niemi, M. (2015) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000148 · Cited by 409
Self-citationThe pancreatic cancer genome revisited
Hayashi, A., Hong, J., & Iacobuzio-Donahue, C. A. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00463-z · Cited by 211
Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA)
Chin, R.-I., Chen, K., Usmani, A., Chua, C., Harris, P. K., Binkley, M. S., Azad, T. D., Dudley, J. C., & Chaudhuri, A. A. (2019) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-019-00390-5 · Cited by 191
Tsamandouras, N., Dickinson, G., Guo, Y., Hall, S., Rostami-Hodjegan, A., Galetin, A., & Aarons, L. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.55 · Cited by 68
Metadata
- Authors
- Nies, A. T., Niemi, M., Burk, O., Winter, S., Zanger, U. M., Stieger, B., Schwab, M., & Schaeffeler, E.
- Venue
- Genome Medicine
- Published
- 2013-01-11
- Volume
- 5
- Issue
- 1
- Pages
- 1-1
- ISSN
- 1756-994X (ISSN-L)
- OpenAlex
- W2111212838
- Cited by
- 265
- References
- 74
- FWCI
- 25.52
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.